Stock Price Quote

ELEGANT PHARMACEUTICALS LTD.

NSE : NABSE : 524344ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1990
Management Info
- Chairman - Managing Director
Registered Office

Address Plot No. A-28, T.T.C. Industrial Area, Khairane,
Navi Mumbai,
Maharashtra-400705

Phone

Email --

Website NA

Registrars Details
Gee Kay Textiles Ltd
,,,Hisar
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR Mar 11 ANNUAL 11
Net Profit-0.02-0.11
Gross Profit -0.02 -0.11
Operating Profit 0.060.21
Net Sales 0.120.42

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  8961.30 (1.51%)
M.Cap ( in Cr)20672.06
Divi's Lab (BSE)
peergroup  4005.90 (2.02%)
M.Cap ( in Cr)105372.44
NGL Fine-Chem (BSE)
peergroup  2378.80 (2.00%)
M.Cap ( in Cr)1454.15
Astrazeneca Pharma I (BSE)
peergroup  5797.00 (0.69%)
M.Cap ( in Cr)14354.75
Orchid Pharma (BSE)
peergroup  1098.85 (2.34%)
M.Cap ( in Cr)5507.84

Shareholding Pattern

NON-INSTITUTION 62.85%
PROMOTERS 37.15%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.